Subperiosteal abscess in pediatric acute osteomyelitis: ultrasound-guided percutaneous aspiration in three cases.

Skeletal RadiolMay 29, 2026 (epub)
Case ReportPediatricsOrthopedic SurgeryOpen access

Gonzalo Corral

✦ AI-curated · Sources linked

Case in brief

Three pediatric patients with acute osteomyelitis developed subperiosteal abscesses, traditionally treated with surgical drainage. Ultrasound revealed abscesses measuring 4-7 mm, with no significant intraosseous involvement. They underwent ultrasound-guided percutaneous aspiration, yielding purulent material positive for methicillin-sensitive Staphylococcus aureus. All patients experienced rapid clinical improvement within 24-48 hours, with no complications or need for further surgical intervention.

Diagnostic / clinical pearl

Ultrasound-guided percutaneous aspiration can be an effective, minimally invasive treatment for subperiosteal abscesses in pediatric patients with acute osteomyelitis.

Why it matters

This approach may reduce the need for more invasive surgical procedures, highlighting the importance of considering ultrasound guidance in similar cases.

Source

PubMed · PMID 42213105Free full text on PubMed Central

Published in Skeletal Radiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.